Companies › Dompé Farmaceutici
2 active drug programs in 5 registered trials: 3 Phase 3, 1 Phase 4, 1 Phase 2; Ophthalmology, Neurology, Immunology, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DFL24498 | – | Phase 3 | Atopic Keratoconjunctivitis; Dry Eye Disease (DED) | Dec 2026 |
| Cenegermin Neurotrophic tyrosine kinase receptor agonist | NTRK1, NTRK2, NTRK3 | Phase 3 | Non-Arteritic Anterior Ischemic Optic Neuropathy; Persistent Corneal Epithelial Defect; Dry Eye | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06947850 | Cenegermin | Phase 4 | Dry Eye | Ophthalmology | Sep 2025 |
| NCT07503886 | DFL24498 | Phase 2 | Dry Eye Disease (DED) | Ophthalmology | Dec 2026 |
| NCT07395232 | DFL24498 | Phase 3 | Atopic Keratoconjunctivitis | Respiratory | Mar 2027 |
| NCT07453888 | Cenegermin | Phase 3 | Non-Arteritic Anterior Ischemic Optic Neuropathy | Neurology | Sep 2027 |
| NCT07519902 | Cenegermin | Phase 3 | Persistent Corneal Epithelial Defect | Immunology | Dec 2027 |
Andover Research Eye Institute Regenerative Ocular Immunobiologics SANGMYUNG innovation Cloudbreak Therapeutics YS Life Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.